# Eton Pharmaceuticals (ETON) — Earnings

ETON · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/eton/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $0.35 |
| EPS estimate | $0.15 |
| EPS surprise | +137.45% |
| Revenue surprise | +38.67% |
| Revenue | $37.6M |
| Revenue estimate | $27.1M |
| Reported | Aug 13, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1710340/000143774926027684/eton20260630_10q.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/a4be6163-aa7e-eed6-51ab-7019336545f3.html) |

Eton Pharmaceuticals reported Q2 2026 results on August 13, 2026. EPS was $0.35, well above the $0.15 estimate, a 137.45% beat. Revenue reached $37.6 million against a $27.1 million estimate. A year earlier, Q2 2025 was a loss of $0.10 per share on revenue of $18.9 million, so revenue nearly doubled, up 98.9%.

The table shows a company moving from losses to profits. Twelve of the 20 quarters were losses, the latest in Q2 2025. Annual EPS was a loss of $0.35 in 2022, $0.03 in 2023 and $0.15 in 2024, then a small profit of $0.05 in 2025. Revenue rose from $21.3 million in 2022 to $80.0 million in 2025. The last four quarters were all profitable, and Q2 2026 set the highs in the table for both EPS and revenue. Against estimates the record is mixed: 10 beats and 10 misses over the last 20 quarters, with large percentage surprises because many estimates were close to zero.

Eton reported Q3 between November 6 and November 15 in each of the past five years, which points to early or mid-November 2026 for the next report. It will show whether profits hold after four positive quarters in a row.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 13, 2026 | $0.15 | $0.35 | 137.45% | $27.1M | $37.6M |
| Q1 2026 | May 14, 2026 | $0.11 | $0.14 | 23.57% | $22.3M | $24.3M |
| Q4 2025 | Mar 19, 2026 | $0.13 | $0.17 | 27.53% | $20.0M | $21.3M |
| Q3 2025 | Nov 6, 2025 | $0.09 | $0.04 | -55.56% | $20.5M | $22.5M |
| Q2 2025 | Aug 7, 2025 | −$0.04 | −$0.10 | -172.48% | $16.7M | $18.9M |
| Q1 2025 | May 13, 2025 | $0.05 | −$0.06 | -212.57% | $15.1M | $17.3M |
| Q4 2024 | Mar 18, 2025 | −$0.00 | −$0.02 | -506.06% | $10.5M | $11.6M |
| Q3 2024 | Nov 12, 2024 | −$0.01 | $0.02 | 300.00% | $9.7M | $10.3M |
| Q2 2024 | Aug 8, 2024 | −$0.07 | −$0.12 | -71.43% | $8.8M | $9.1M |
| Q1 2024 | May 9, 2024 | −$0.07 | −$0.03 | 57.14% | $7.7M | $8.0M |
| Q4 2023 | Mar 14, 2024 | −$0.04 | −$0.09 | -125.00% | $7.7M | $7.3M |
| Q3 2023 | Nov 9, 2023 | −$0.10 | −$0.02 | 80.00% | $6.3M | $7.0M |
| Q2 2023 | Aug 10, 2023 | −$0.09 | $0.18 | 300.00% | $6.5M | $12.0M |
| Q1 2023 | May 11, 2023 | −$0.14 | −$0.10 | 28.57% | $4.6M | $5.3M |
| Q4 2022 | Mar 16, 2023 | $0.01 | $0.04 | 300.00% | $9.1M | $8.5M |
| Q3 2022 | Nov 10, 2022 | −$0.15 | −$0.12 | 20.00% | $3.0M | $3.2M |
| Q2 2022 | Aug 11, 2022 | $0.03 | −$0.06 | -300.00% | $7.8M | $7.4M |
| Q1 2022 | May 12, 2022 | −$0.08 | −$0.21 | -162.50% | $7.1M | $2.2M |
| Q4 2021 | Mar 16, 2022 | $0.05 | $0.04 | -20.00% | $7.6M | $6.1M |
| Q3 2021 | Nov 15, 2021 | −$0.14 | −$0.24 | -77.78% | $3.0M | $775,000.00 |

## Frequently Asked Questions

### When did Eton Pharmaceuticals (ETON) last report earnings?

Eton Pharmaceuticals last reported on Aug 13, 2026, covering fiscal Q2 2026.

### Did ETON beat earnings estimates?

Yes. Eton Pharmaceuticals reported EPS of $0.35 for Q2 2026 against a $0.15 estimate — a 137.45% beat.

### How much revenue did ETON report last quarter?

Eton Pharmaceuticals reported $37.6M in revenue for Q2 2026, against a consensus estimate of $27.1M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).